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Abstract
Background: Stroke is a leading cause of death and disability worldwide. Identifying the aetiology of ischaemic
stroke is essential in order to initiate appropriate and timely secondary prevention measures to reduce the risk of
recurrence. For the majority of ischaemic strokes, the aetiology can be readily identified, but in at least 30% of
cases, the exact aetiology cannot be determined using existing investigative protocols. Such strokes are classed as
‘cryptogenic’ or as a stroke of unknown origin. However, there exists substantial variation in clinical practice when
investigating cases of seemingly cryptogenic stroke, often reflecting local service availability and the preferences of
treating clinicians. This variation in practice is compounded by the lack of international consensus as to the
optimum level and timing of investigations required following a stroke. To address this gap, we aim to
systematically review and compare recommendations in evidence-based clinical practice guidelines (CPGs) that
relate to the assessment and investigation of the aetiology of ischaemic stroke, and any subsequent diagnosis of
cryptogenic stroke.
Method: We will search for CPGs using electronic databases (MEDLINE, Health Management Information
Consortium (HMIC), EMBASE, and CINAHL), relevant websites and search engines (e.g. guideline specific websites,
governmental, charitable, and professional practice organisations) and hand-searching of bibliographies and
reference lists. Two reviewers will independently screen titles, abstracts and CPGs using a pre-defined relevance
criteria form. From each included CPG, we will extract definitions and terms for cryptogenic stroke;
recommendations related to assessment and investigation of the aetiology of stroke, including the grade of
recommendations and underpinning evidence. The quality of the included CPGs will be assessed using the AGREE
II (Appraisal of Guidelines for Research and Evaluation) tool. Recommendations across the CPGs will be summarised
descriptively highlighting areas of convergence and divergence between CPGs.
Discussion: To our knowledge, this will be the first review to systematically compare recommendations of
international CPGs on investigating the aetiology of ischaemic stroke. The findings will allow for a better
understanding of international perspectives on the optimum level of investigations required following a stroke and
thus contribute to achieving greater international consensus on best practice in this important and complex area.
Systematic review registration: PROSPERO CRD42019127822.
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Background
Globally, stroke is the second most common cause of
death [1] and the third most common cause of disability
[2]. In the UK alone, the direct and indirect costs of
stroke are around £26bn per year [3]. Those who survive
an initial stroke are at high risk of further stroke [4], and
a quarter of all stroke survivors will have a further stroke
within 5 years [5]. These subsequent strokes are associ-
ated with worse outcomes and an even higher mortality
than the initial stroke [6]. It is therefore essential that
the aetiology of a stroke can be identified, not only to
guide treatment for specific conditions, but also to initi-
ate appropriate and timely secondary prevention to re-
duce the risk of recurrence [7].
Although most ischaemic strokes are caused by ath-
erosclerosis or arteriosclerosis of the blood vessels
within the brain, or embolism originating from the
heart or the major extracranial blood vessels, in at least
30% of cases, the exact aetiology of an ischaemic stroke
is not identifiable by existing investigative protocols
[8]; this is classed as a cryptogenic stroke or stroke of
unknown origin. Classifying an ischaemic stroke as
‘cryptogenic’ is therefore based on the exclusion of
other well-established causes of stroke [9], and with
more than 200 possible causes of a stroke, arriving at
this classification can pose a formidable challenge to
clinicians [10]. Standard diagnostic workup of patients
tends to include brain imaging, vascular imaging and
cardiac evaluations [8]. If these investigations fail to
identify the aetiology of the stroke, further investiga-
tions tend to depend on local service availability and
on the preference of the treating clinician. Therefore, a
‘diagnosis’ of cryptogenic stroke is often allocated
loosely in the absence of a thorough workup, rather
than the cause truly being unknown. This has import-
ant implications especially in light of the lack of avail-
able options for secondary prevention for strokes of
unknown source. For example, two recent randomised
trials of non-vitamin K antagonist oral anticoagulants
did not show a reduction in recurrent stroke compared
to aspirin [11, 12], and one of these showed possible
harm with an excess of bleeding [11]. This is in con-
trast to the well-established benefits for stroke preven-
tion with oral anticoagulation in patients where a
cardiogenic cause such as atrial fibrillation is found
[13]. Patients whose stroke is labelled as cryptogenic
are unable to take steps to reduce their risk of a subse-
quent stroke.
Diagnostic workup in cases of seemingly cryptogenic
stroke is highly complex, and from existing guidelines,
it is difficult to discern specific recommendations for
diagnostic pathways. Additionally, up to now, only one
diagnostic algorithm has been proposed to classify
cryptogenic stroke [10]. This algorithm has identified
three levels of investigation in an hierarchical fashion :
(1) standard level, which may be considered the abso-
lute minimum, (2) advanced level, and (3) highly spe-
cialised level where an even more advanced set of
investigations may be performed. These recommenda-
tions are in line with the American Heart Association–
American Stroke Association and American Academy
of Neurology guidelines [14–17].
As such, while some guidelines and published diag-
nostic algorithms have been proposed to facilitate the
identification of the aetiology of ischaemic stroke, there
does not yet exist international consensus on the
optimum level and timing of investigations required
following a stroke. Therefore, we aim to review inter-
national clinical practice guidelines (CPGs) to compare
recommendations and pathways for the diagnostic
workup necessary before arriving at the diagnosis of
cryptogenic stroke, to understand where there are
agreement, disagreement and conflicting recommenda-
tions. The review findings will inform prioritisation of
future research in this emerging field of inquiry.
Aim
The aim is to compare and appraise recommendations
in evidence-based international clinical practice guide-
lines (CPGs) that relate to the assessment and investiga-
tion of the aetiology of ischaemic stroke and any
subsequent diagnosis of cryptogenic stroke.
Methods
The review has been designed based on input from ex-
perts in stroke and systematic review methodology and
in accordance with the Preferred Reporting Items for
Systematic review and Meta-Analysis Protocols
(PRISMA-P) guidance. A PRISMA-P reporting checklist
is provided in Additional file 1. The review is registered
on PROSPERO, number: CRD42019127822.
Eligibility criteria
We will include CPGs that
1. Have been endorsed by a national and/or
international organisation (e.g. governmental,
charitable and professional practice)
2. Include recommendations related to the assessment
and investigation of the aetiology of ischaemic
stroke and any subsequent diagnosis of cryptogenic
stroke
3. Were published from January 2009 onwards (to
ensure only the most up-to-date guidelines were
included)
4. Are available in English
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CPGs focused exclusively on treatment and rehabilita-
tion of stroke will be excluded.
Information sources and search strategy
Relevant CPGs will be retrieved using a combination of
search strategies: (1) searching electronic databases, (2)
searching relevant websites, (3) targeted searches by coun-
try and (4) hand-searching reference lists of included
guidelines. Medical Subject Headings and text words such
as ‘clinical practice guidelines’ and ‘stroke’ will be used to
search electronic databases MEDLINE, Health Manage-
ment Information Consortium (HMIC), EMBASE, and
CINAHL. A draft search strategy for MEDLINE is pro-
vided in Additional file 2. As CPGs are often not included
in electronic databases, we will also systematically search
for guidelines using popular search engines and relevant
websites. These websites will include, but are not limited
to, the American Academy of Neurology website (https://
www.aan.com/), the Cochrane Library, Guidelines Inter-
national Network (www.g-i-n.net); National Institute for
Health and Care Excellence (https://www.nice.org.uk/),
Scottish Intercollegiate Guidelines Network (https://www.
sign.ac.uk/) and along with grey literature repositories (e.g.
Open Grey (http://www.opengrey.eu/)). We will use key-
words in the search utilities of each website to identify po-
tentially relevant guidelines and conduct targeted searches
by country. We will screen all relevant results retrieved
through these searches. A final list of all relevant CPGs
identified through this search strategy will be shared with
the expert steering group to identify any additional CPGs
that could contribute to the review aims and/or confirm
that no relevant CPGs, of which the steering group mem-
bers are already aware, have been omitted.
Study selection
One reviewer (NMcM) will collate all retrieved citations
into reference management software for screening. Two
reviewers (NMcM/MB) will independently screen all re-
trieved citations using a pre-defined relevance criteria
form. For potentially relevant CPGs, the full texts will be
obtained and independently assessed by two reviewers
(from NMcM/MB/EB/RG/JG), including at least one
with extensive experience of working in a clinical role in
stroke care. Disagreements at any stage will be resolved
through discussion with a third reviewer.
Data collection process and data items
A bespoke data extraction form will be developed,
piloted and modified as necessary. One reviewer will ex-
tract all relevant information using this form. A second
reviewer will perform a full check of the data extraction
for all included guidelines to verify the accuracy of data
extraction. Any disagreements will be resolved through
discussion with a third reviewer. We will extract the
following information from each CPG: year of dissemin-
ation; country/region; organisation; development team;
funding; definition or terms used to describe cryptogenic
stroke; recommendations related to assessment, investi-
gation and diagnosis of stroke aetiology (including the
recommended timing and order of investigations); rec-
ommendations related to the diagnosis of cryptogenic
stroke; research evidence cited; and qualifying terms
(such as level of evidence or grade of recommendation)
used to summarise the strength of recommendations
and their underpinning evidence.
Quality appraisal
We will appraise the quality of the included CPGs using
the Appraisal of Guidelines Research and Evaluation
(AGREE) II [18] tool which assesses the scope and pur-
pose, stakeholder involvement, rigour of development,
clarity and presentation, applicability and editorial inde-
pendence. As recommended, each guideline will be inde-
pendently assessed by four reviewers [19], and average
ratings calculated to produce a quality score for each of
the six domains. In line with similar reviews, we will as-
sess agreement for each domain item and collectively re-
view items where appraisers scores were > 1.5 standard
deviations (SD) from the mean item score [20]. A do-
main will be considered to be adequately addressed if
scoring ≥ 60% [20–23].
Synthesis
Recommendations related to assessment, investigation
and diagnosis of stroke aetiology and diagnosis of
cryptogenic stroke will be summarised descriptively. We
will evaluate whether guidelines made specific recom-
mendations and, in the cases where this is done, we will
describe the grade of the recommendation, the level of
evidence supporting the recommendation, and where
the level of details allows, the nature and quality of stud-
ies supporting/refuting the recommendation. We will or-
ganise the identified recommendations into categories
using a recently published identification and diagnostic
evaluation algorithm [10] and produce summary tables
to illustrate where there is consensus or disagreement
between recommendations presented in the individual
CPGs. Finally, we will compare the recommendations
identified in each of the CPGs with the diagnostic evalu-
ation algorithm to assess the extent to which there is
agreement between each recommendation [10].
Discussion
This review forms part of a wider programme of work
exploring the optimisation of assessment and investiga-
tion of the aetiology of ischaemic stroke and the diagno-
sis of cryptogenic stroke. To our knowledge, this will be
the first systematic review to compare the content of
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recommendations in relevant international CPGs. The
review findings will allow for a better understanding of
similarities and differences in international recommen-
dations for identifying the aetiology of a stroke, the
optimum level of investigations required following a
stroke and the quality of evidence underpinning practice
recommendations. Additionally, the review findings will
have practical implications for the detection and man-
agement of patients with cryptogenic stroke. This review
will follow a robust systematic method to identify all
relevant publications. It will however only include Eng-
lish language publications which are a limitation.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13643-019-1247-6.
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